BiotechTube

ADL5747 + Placebo + Pregabalin

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postherpetic Neuralgia

Conditions

Postherpetic Neuralgia

Trial Timeline

Jan 1, 2010 → Dec 1, 2010

NCT ID
NCT01058642

About ADL5747 + Placebo + Pregabalin

ADL5747 + Placebo + Pregabalin is a phase 2 stage product being developed by Merck for Postherpetic Neuralgia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01058642. Target conditions include Postherpetic Neuralgia.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01058642Phase 2Terminated

Competing Products

20 competing products in Postherpetic Neuralgia

See all competitors
ProductCompanyStageHype Score
QUTENZAAstellas PharmaApproved
85
KHK6188 + PlaceboKyowa KirinPhase 2
52
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
52
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3
77
MK-8291 + PlaceboMerckPhase 1
33
Etoricoxib + PlaceboMerckApproved
85
MK0759MerckPhase 2
52
MK0686MerckPhase 2
52
Comparator: pregabalin + Comparator: Placebo (unspecified)MerckPhase 1
33
Lyrica (pregabalin) + PlaceboPfizerApproved
84
RN624 + RN624 + PlaceboPfizerPhase 2
51
T-62PfizerPhase 2
51
pregabalin + pregabalin/PF-00489791 + PlaceboPfizerPhase 2
51
PH-797804 + PlaceboPfizerPhase 2
51
Placebo + Pregabalin + Pregabalin + PregabalinPfizerPhase 3
76
pregabalinPfizerPhase 3
76
pregabalinPfizerApproved
84
T-62 Dose 1 + T-62 Dose 2PfizerPhase 2
51
HSK16149 20mg BID + HSK16149 40mg BID + Placebo BIDHaisco Pharmaceutical GroupPhase 3
74
LevetiracetamUCBPhase 2
49

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85